Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented osteoporosis of the femoral neck and lumbar spine~Exclusion Criteria:~* BMI greater than or equal to 35

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo tablet once a week for 2 years followed by once a week Risedronate for 2 years
- Risedronate (Type: EXPERIMENTAL): 35 mg risedronate tablet once a week for 2 years followed by open label 35 mg risedronate once a week for 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).